These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 18546628)

  • 21. Induction of Akt activity by chemotherapy confers acquired resistance.
    Huang WC; Hung MC
    J Formos Med Assoc; 2009 Mar; 108(3):180-94. PubMed ID: 19293033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in molecular targets and cancer therapeutics.
    Westwell AD
    Drug Discov Today; 2004 Mar; 9(5):207-9. PubMed ID: 14980538
    [No Abstract]   [Full Text] [Related]  

  • 23. Lung cancer proteomics, clinical and technological considerations.
    Lehtiö J; De Petris L
    J Proteomics; 2010 Sep; 73(10):1851-63. PubMed ID: 20685322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere.
    Shao T; Wang J; Chen JG; Wang XM; Li H; Li YP; Li Y; Yang GD; Mei QB; Zhang SQ
    Eur J Med Chem; 2014 Mar; 75():96-105. PubMed ID: 24530495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphatidylinositol-3-kinase pathway.
    Reckamp KL
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S383-4. PubMed ID: 23160326
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of chemoresponse assays as predictive markers.
    Korn EL; Freidlin B
    Br J Cancer; 2015 Feb; 112(4):621-3. PubMed ID: 25584494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer biomarkers: current issues and future directions.
    Jain KK
    Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
    Fruman DA; Rommel C
    Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the PI3K pathway: hope we can believe in?
    van der Heijden MS; Bernards R
    Clin Cancer Res; 2010 Jun; 16(12):3094-9. PubMed ID: 20400520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.
    Leroy C; Amante RJ; Bentires-Alj M
    Biochem Soc Trans; 2014 Aug; 42(4):733-41. PubMed ID: 25109950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
    Britten CD
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1395-409. PubMed ID: 23443307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rapidly growing number of therapeutics targeting tumor cell-intrinsic and -extrinsic processes is under development for individualized treatment of cancer patients.
    Giske CG; Jonkers J
    Drug Resist Updat; 2012; 15(1-2):1. PubMed ID: 22326647
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimal targeting of the mTORC1 kinase in human cancer.
    Lane HA; Breuleux M
    Curr Opin Cell Biol; 2009 Apr; 21(2):219-29. PubMed ID: 19233631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to comment on: 'evaluation of chemoresponse assays as predictive biomarkers'.
    Korn EL; Freidlin B
    Br J Cancer; 2015 Jun; 112(12):1978. PubMed ID: 25965166
    [No Abstract]   [Full Text] [Related]  

  • 35. Comment on: 'evaluation of chemoresponse assays as predictive markers'.
    Tian C; Gabrin MJ; Brower SL; Sargent DJ
    Br J Cancer; 2015 Jun; 112(12):1977-8. PubMed ID: 25989277
    [No Abstract]   [Full Text] [Related]  

  • 36. NCI CPTI: technologies for proteomics.
    Cottingham K
    J Proteome Res; 2006 Oct; 5(10):2502. PubMed ID: 17076037
    [No Abstract]   [Full Text] [Related]  

  • 37. Challenges and opportunities in oncoproteomics.
    Celis JE; Moreira JM
    Mol Oncol; 2010 Dec; 4(6):459-60. PubMed ID: 20980210
    [No Abstract]   [Full Text] [Related]  

  • 38. Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.
    Cummings J; Raynaud F; Jones L; Sugar R; Dive C
    Br J Cancer; 2010 Oct; 103(9):1313-7. PubMed ID: 20924371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of genomics and proteomics in the clinic: functional genetic polymorphisms and their value in response and toxicity prediction in solid tumours.
    Stoehlmacher J
    Ann Oncol; 2006 Sep; 17 Suppl 10():x263-8. PubMed ID: 17018736
    [No Abstract]   [Full Text] [Related]  

  • 40. Letting biology do the work.
    Sikora K
    Drug Discov Today; 2003 Mar; 8(6):248-9. PubMed ID: 12623235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.